Amicus Therapeutics Inc: (NASD: FOLD)

$2.54

-0.65 (-20.38%)

Volume 3,030,943

Jun 17 03:59 PM ET

Zacks Rank: 3-Hold

 
 
#3
 
 

Overview Quote

Get Overview Quote for:

Stock Activity

Day Low - High 2.30 - 2.63
52wk Low - High 2.30 - 6.89
Previous Close 3.19
Avg. Volume 297,532
Industry MED-BIOMED/GENE
Market Cap 158.33 M
Div - Yield 0.00 - 0.00
Beta 0.94
P/E (F1) 0.00
Current Year Est. -1.35
Quarterly Earnings ESP NA

Premium research

Zacks Rank Short-Term: 1-3 Months

Zacks #1 Rank Strong Buys

3

Zacks Recommendation Long-Term: 6+ Months

All Outperform Rated Stocks

Neutral

Zacks Industry Rank

102 out of 265

Equity Research Report

Updated as of 06/5/2013

PREMIUM

( = Change in last 30 days)

Get all our stock ratings and recommendations with a Free Trial to Zacks Premium Start Free Trial

Key Earnings Data

P/E (F1) NA
PEG Ratio NA
Current Year Est. -1.35
Current Quarter Estimate -0.32
Most Accurate Estimate NA
Earnings ESP NA
Next Earnings Report Date 08-06-2013
EPS Last Year -1.12
Expected Earnings Growth NA

Company Description

AMICUS THERAPEUTICS is a biopharmaceutical company developing novel, oral therapeutics known as pharmacological chaperones for the treatment of a range of human genetic diseases. Pharmacological chaperone technology involves the use of small molecules that selectively bind to and stabilize proteins in cells, leading to improved protein folding and trafficking, and increased activity. Amicus is initially targeting lysosomal storage disorders, which are severe, chronic genetic diseases with unmet medical needs. Amicus has completed Phase 2 clinical trials of Amigal(TM) for the treatment of Fabry disease and is conducting Phase 2 clinical trials of Plicera(TM) for the treatment of Gaucher disease.

NYSE data is at least 20 minutes delayed.

NASDAQ data is at least 15 minutes delayed.

Interactive Java Charting | Fundamental Charts

Introducing Zacks Whisper Trader

Turn Earnings Surprises into quick profits.

 

FOLD Chart by YCharts

Earnings Estimates

Current Qtr
(06/2013)
Next Qtr
(09/2013)
Current Year
(12/2013)
Next Year
(12/2014)
Average Estimate -0.32 -0.34 -1.35 -1.26
Number of Estimates 4 4 4 4
Low Estimate -0.35 -0.37 -1.44 -1.67
High Estimate -0.28 -0.29 -1.21 NA
Year Ago EPS -0.20 -0.35 -1.08 -1.35
EPS Growth -62.50% 4.29% -25.00% 6.85%

Average Earnings Estimates for FOLD

EPS Growth for FOLD

Industry Analysis

Name Symbol Previous Close Zacks Rank Zacks Recommendation
AMICUS THERAPT FOLD 3.19
AETERNA ZENTARS AEZS 1.93
ANIKA THERAPEUT ANIK 15.68
BIOGEN IDEC INC BIIB 211.99
MYRIAD GENETICS MYGN 27.59
PROTALIX BIOTHR PLX 4.98
ADDEX THERA LTD ADDXF 4.36
AFFYMAX INC AFFY 1.10
ALEXION PHARMA ALXN 92.22
ALNYLAM PHARMA ALNY 30.11

Sector:Medical>> Industry:MED-BIOMED/GENE

COMPARE TICKER vs. Its Peers

Financials

EPS TTM -1.12
Sales 18
Net Income -53
Price/Earnings NA
Price/Book 2.97
Price/Cash Flow NA
Price/Sales 5.31

Zacks Research is Reported On:

Zacks Investment Research

is an A+ Rated BBB

Accredited Business.